The 8,000-square-meter facility in Uppsala will support global supply chain for allergy and autoimmune disease testing.
Thermo Fisher Scientific Inc. has opened a new $18 million distribution and labeling center in Uppsala, Sweden, to strengthen its global supply chain for immunodiagnostics products used in allergy and autoimmune disease testing.
The 8,000-square-meter facility supports the company’s immunodiagnostics business and is designed to handle future growth in demand from healthcare systems worldwide. The center features automated storage, scanning, and labeling systems to improve efficiency, accuracy, and traceability of diagnostic products.
“The investment in the distribution and labeling center is part of our long-term growth strategy in Sweden and reflects our commitment to meeting future customer demand globally,” says Martin Kjellsson, site leader for Thermo Fisher’s immunodiagnostics business in Uppsala, in a release. “By strengthening our logistics capabilities, we are better positioned to scale for future volume while continuing to deliver high-quality products and service to our customers.”
Supporting Global Diagnostic Demand
Allergic and autoimmune diseases affect as many as 2 billion people globally, according to the company. From its Uppsala hub, Thermo Fisher manufactures diagnostic tests that support clinicians in diagnosing and managing these conditions for millions of patients annually.
The new facility complements Thermo Fisher’s existing research, development, and manufacturing activities in Uppsala. It enhances the company’s ability to scale logistics operations and ensure reliable delivery of diagnostic products to customers worldwide.
Thermo Fisher’s immunodiagnostics operations in Uppsala develop and manufacture diagnostic solutions for asthma, allergy, and autoimmune diseases. The business traces its roots to scientific research conducted at Uppsala University, where researchers played a key role in discovering immunoglobulin E more than 50 years ago, laying the foundation for modern allergy diagnostics.
Product Portfolio and Future Investment
The company’s diagnostics portfolio includes instruments marketed under the Phadia brand, as well as ImmunoCAP and EliA tests.
“Our immunodiagnostics business is focused on enabling patients around the world to receive a timely and accurate diagnosis for allergic and autoimmune diseases,” says Santhosh Nair, president of Thermo Fisher’s immunodiagnostics business, in a release. “This investment in Uppsala reflects our continued commitment to innovation, operational excellence, and to our mission to enable our customers to make the world healthier, cleaner, and safer.”
The distribution center was developed according to Thermo Fisher’s global facility standards and incorporates energy-efficient design features. The company continues to invest in research and development capabilities globally and in Sweden, building on Uppsala’s life science ecosystem and academic connections.
Thermo Fisher Scientific employs more than 1,500 people in Sweden across five locations: Uppsala, Stockholm, Gothenburg, Sundbyberg, and Ängelholm.
ID 327002597 © Juan Alejandro Bernal | Dreamstime.com
